Clinical Trials Logo

Filter by:
NCT ID: NCT05997927 Recruiting - Clinical trials for Moderate to Severe Atopic Dermatitis

Efficacy and Safety Clinical Study of VC005 Tablets in Adult Patients With Moderate to Severe Atopic Dermatitis

Start date: July 20, 2023
Phase: Phase 2
Study type: Interventional

This clinical trial is a multicenter, randomized, double-blind, controlled phase II clinical study.

NCT ID: NCT05997719 Recruiting - Clinical trials for Non-small Cell Lung Cancer

Exploring Cancer Evolution, Prognostic and Predictive Biomarkers in EGFR-mutant NSCLC

Start date: August 10, 2023
Phase:
Study type: Observational

To investigate genomic architecture, cancer evolution and their relationship with clinical outcomes in EGFR-mutant NSCLC.

NCT ID: NCT05997667 Recruiting - Parkinson Disease Clinical Trials

Study on the Efficacy and Safety of Rechargeable Implantable DBS System in the Treatment of Parkinson's Disease

Start date: July 20, 2023
Phase: N/A
Study type: Interventional

The purpose of this clinical trial is to verify the efficacy and safety of rechargeable implantable deep brain stimulation (DBS) system for the treatment of advanced primary Parkinson's disease.

NCT ID: NCT05997602 Recruiting - Clinical trials for Langerhans Cell Histiocytosis

To Evaluate the Efficacy, Safety, and PK Characteristics of FCN-159 in Pediatric Patients With Refractory/Recurrent LCH

Start date: September 28, 2023
Phase: Phase 2
Study type: Interventional

This is a rare disease, single-arm, open-label,multi-center, non-randomized Phase 2 clinical study to evaluate the efficacy, safety, and pharmacokinetic characteristics of FCN-159 monotherapy in pediatric patients with refractory/recurrent Langerhans cell histiocytosis (LCH).

NCT ID: NCT05997433 Recruiting - Clinical trials for Helicobacter Pylori Infection

Efficacy of 7-day Versus 14-day Bismuth Quadruple Therapy for the Eradication of Helicobacter Pylori(SHARE2302)

Start date: September 2, 2023
Phase: N/A
Study type: Interventional

Helicobacter pylori (H. pylori) infection is a common global infectious disease of the gastrointestinal tract. Helicobacter pylori eradication can effectively prevent the development of gastric cancer.The researchers collect H.pylori-positive patients who need native therapy. The subjects were randomized to receive7 days and 14 days of bismuth quadruple eradication therapy. 6-8 weeks after treatment, the subjects will re-take the 13C-urea breath test. Calculate the eradication rates, adverse reaction rates and patient compliance of each group.

NCT ID: NCT05997173 Recruiting - Oral Lichen Planus Clinical Trials

The Regulatory Role of Immune Response in Oral Lichen Planus

Start date: September 7, 2020
Phase:
Study type: Observational

Oral lichen planus (OLP) is a common chronic inflammatory disease of Oral mucosa. The pathogenesis of OLP is not clear, and there is no effective method to cure it. In vitro, previous studies have shown that oral mucosal mesenchymal stem cell cells (MSCs) can secrete Ido, which is involved in the pathogenesis of OLP. It has been proved that mental disorders such as depression and anxiety play an important role in the pathogenesis and treatment of OLP. Mental stress factors can cause abnormal changes of inflammatory factors, leading to immune dysfunction, which is also one of the main causes of OLP. In this study, we integrated the advantages of stomatology, psychiatry, neurobiology and traditional Chinese medicine, focused on the clinical problems of mental disorders with oral mucosal comorbidity, and assessed the depressive and anxiety status of OLP patients, so as to improve the therapeutic effect of OLP.

NCT ID: NCT05997147 Recruiting - Pancreas Cancer Clinical Trials

A Preoperative Model to Predict the Lymphovascular Invasion in Pancreatic Ductal Adenocarcinoma

Start date: May 1, 2023
Phase:
Study type: Observational

Importance: Lymphovascular invasion (LVI) is a poor prognosis pathologic feature in pancreatic ductal adenocarcinoma (PDAC) patients. Neoadjuvant therapy may bring survival benefits to these patients. Objective: To construct a preoperative model which could predict LVI in PDAC patients and further validate it in other cohorts. Design, Setting, and Participants: Patients from 3 three tertiary hospitals were included in this study. Univariate and multivariate Logistic regression analyses were conducted to define independent prediction factors of LVI. A nomogram was constructed based on the result of multivariate analysis.The predictive value of the model was assessed using receiver operating characteristic (ROC) curves and the maximum Youden index of the ROC curve was defined as the cut-off point. The calibration plot was utilized to assess the concordance of the model. The decision curve analyses (DCA) were applied to estimate the clinical benefit of using this model to predict LVI.

NCT ID: NCT05997043 Recruiting - Parkinson's Disease Clinical Trials

Safety and Efficacy of Botulinum Toxin A for Treatment of Overactive Bladder in Parkinson's Disease

Start date: August 26, 2023
Phase: Early Phase 1
Study type: Interventional

A randomized controlled trial is to be conducted to confirm the efficacy and safety of intramuscular injection of botulinum toxin in the treatment of Parkinson's bladder overactivity.

NCT ID: NCT05996848 Recruiting - Clinical trials for Obesity or Overweight

A Research Study to See How Well CagriSema Helps People in China With Excess Body Weight Lose Weight

REDEFINE 6
Start date: August 15, 2023
Phase: Phase 3
Study type: Interventional

This study will look at how well the new medicine CagriSema helps people with excess body weight losing weight compared to a "dummy" medicine and a medicine called semaglutide. Participants will either get CagriSema, a dummy medicine or semaglutide. Which treatment participants get is decided by chance. Participants will take one injection once a week. The study medicine will be injected briefly with a thin needle, typically in the stomach, thighs or upper arms. The study will last for about 1 year.

NCT ID: NCT05996666 Recruiting - Liver Cancer Clinical Trials

Primary Liver Cancer Early Detection

PRIMe-liver
Start date: July 1, 2023
Phase:
Study type: Observational

In the recently published multi-center, prospective, single-blind study (THUNDER study), using the methylation signal in cfDNA isolated from the peripheral blood to detect the six types of cancer, the sensitivity for liver cancer detection achieved 87.8%, with a specificity of 98.9%. In this study, a multicenter, case-control study is designed to establish an early cancer detection model based on cfDNA methylation biomarkers using qPCR to detect primary liver cancer and further validate the performance of the model.